Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys

Neuropsychopharmacology

Volumn 30, Issue 4, 2005, Pages 758-764

  Gasior, Maciej ^a,c   Bergman, Jack ^a   Kallman, Mary Jeanne ^b   Paronis, Carol A ^a  

^a MCLEAN HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Abuse liability; Amphetamine; Atomoxetine; Desipramine; Methylphenidate; Self administration

Indexed keywords

AMPHETAMINE; ATOMOXETINE; COCAINE; DESIPRAMINE; METHYLPHENIDATE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; AUTOMATION; BEHAVIOR; CONTROLLED STUDY; DECISION MAKING; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG SELF ADMINISTRATION; FEMALE; FOOD INTAKE; INFORMATION PROCESSING; INSTRUMENTATION; MEDICAL LIABILITY; MENTAL TASK; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SUBSTANCE ABUSE; TASK PERFORMANCE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COMPARATIVE STUDY; DESIPRAMINE; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FEMALE; INFUSION PUMPS; MACACA MULATTA; METHYLPHENIDATE; PROPYLAMINES; REINFORCEMENT (PSYCHOLOGY); RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 15444374041     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300593     Document Type: Article

References (44)

1. American Psychiatrie Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn American Psychiatric Association: Washington, DC.
2. Anonymous (2003). Atomoxetine (Strattera) for ADHD. Med Lett Drugs Ther 45: 11-12.
3. Balster RL, Schuster CR (1973). A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys. Pharmacol Biochem Behav 1: 67-71.
4. Bergman J, Madras BK, Johnson SE, Spealman RD (1989). Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251: 150-155.
5. Biederman J (1998). Attention-deficit/hyperactivity disorder: a lifespan perspective. J Clin Psychiatry 59(Suppl 7): 4-16.
6. Biederman J, Newcorn J, Sprich S (1991). Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148: 564-577.
7. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T (1998). Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 44: 269-273.
8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in pre-frontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
9. Czoty PW, Makriyannis A, Bergman J (2004). Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology 175: 170-178.
10. Elia J, Ambrosini PJ, Rapoport JL (1999). Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 340: 780-788.
11. Foltin RW, Fischman MW (1991). Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28: 3-48.
12. Gasior M, Paronis CA, Bergman J (2004). Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys. J Pharmacol Exp Ther 308: 249-259.
13. Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998). Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279: 1100-1107.
14. Griffiths RR, Brady JV, Snell JD (1978). Relationship between anorectic and reinforcing properties of appetite suppressant drugs: implications for assessment of abuse liability. Biol Psychiatry 13: 283-290.
15. Haddad P (1999). Do antidepressants have any potential to cause addiction? J Psychopharmacol 13: 300-307.
16. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF et al (2002). Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67: 149-156.
17. Herd JA, Morse WH, Kelleher RT, Jones LG (1969). Arterial hypertension in the squirrel monkey during behavioral experiments. Am J Physio 27: 24-29.
18. Higgens ES (1999). A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Practice 48: 15-20.
19. Hoffmeister F, Goldberg SR (1973). A comparison of chlorpromazine, imipramine, morphine and d-amphetamine self-administration in cocaine-dependent rhesus monkeys. J Pharmacol Exp Ther 187: 8-14.
20. Iglauer C, Woods JH (1974). Concurrent performances: reinforcement by different doses of intravenous cocaine in rhesus monkeys. J Exp Anal Behav 22: 179-196.
21. Klein-Schwartz W (2002). Abuse and toxicity of methylphenidate. Curr Opin Pediatr 14: 219-223.
22. Klein-Scwartz W, McGrath J (2003). Poison centers' experience with methylphenidte abusein pre-teens and adolescents. J Amer head Child Adolesc Psych 42: 288-294.
23. Kollins SH, MacDonald EK, Rush CR (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68: 611-627.
24. Lamb RJ, Griffiths RR (1990). Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 102: 183-190.
25. Lynch T (2003). Atomoxetine for ADHD. Am Fam Physician 68: 1827-1828.
26. Marks DJ, Newcorn JH, Halperin JM (2001). Comorbidity in adults with attention-deficit/hyperactivity disorder. Ann NY Acad Sci 931: 216-238.
27. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C et al (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901.
28. Michelson D, Paries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR et al (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108: E83.
29. Negus SS (2003). Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28: 919-931.
30. Paronis CA, Gasior M, Bergman J (2002). The effects of cocaine under concurrent fixed ratio schedules of food and i.v. drug availability: a novel choice procedure in monkeys. Psychopharmacology 163: 283-291.
31. Risner ME, Jones BE (1976). Characteristics of unlimited access to self-administered stimulant infusions in dogs. Biol Psychiatry 11: 625-634.
32. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987). Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223.
33. Rush CR, Essman WD, Simpson CA, Baker RW (2001). Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 21: 273-286.
34. Safer DJ, Zito JM, Fine EM (1996). Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98: 1084-1088.
35. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J et al (1998). Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155: 693-695.
36. Spencer TJ, Biederman J, Wilens TE, Faraone SV (2002). Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 63(Suppl 12): 16-22.
37. Sullivan MA, Rudnik-Levin F (2001). Attention deficit/hyperactivity disorder and substance abuse: diagnostic and therapeutic considerations. Ann NY Acad Sci 931: 251-270.
38. Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP (1998). Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351: 429-433.
39. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN et al (1999). Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 65: L7-12.
40. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L et al (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21: RC121.
41. Woolverton WL, Hecht GS, Agoston GE, Katz JL, Newman AH (2001). Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology 154: 375-382.
42. Woolverton WL, Ranaldi R, Wang Z, Ordway GA, Paul IA, Petukhov P et al (2002). Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther 303: 211-217.
43. Yanagita T, Takahashi S, Oinumia N (1972). Drug dependence liability of tricyclic antidepressants evaluated in monkeys. Jpn J Clin Pharmacol 3: 289-294.
44. Zametkin AJ, Ernst M (1999). Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 340: 40-46.